On January 11, 2022 Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") reported that it will provide a progress update on its business and strategic initiatives in a published presentation designed to complement remarks that will be provided by management at 9 a.m. ET tomorrow, Jan. 12, 2022 (Press release, Bausch Health, JAN 11, 2022, View Source [SID1234598606]), during a fireside chat at the 40th Annual J.P. Morgan Healthcare Conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very excited by the progress we have made in our efforts to unlock value across the Company. We are substantially complete in our planning and preparations to launch the Bausch + Lomb and Solta IPOs, subject to market conditions and other approvals and factors," said Joseph C. Papa, chairman and CEO, Bausch Health.1

The presentation is available on the Investor Relations page of the Bausch Health Companies Inc. website at: View Source A live webcast and audio archive of the fireside chat will also be available on the Investor Relations page of the Company’s website.

This news release does not constitute an offer to sell or the solicitation of an offer to buy securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended and otherwise in accordance with applicable securities laws in any other jurisdiction.